Nuvectis Pharma (NVCT) Total Non-Current Liabilities (2022 - 2025)

Nuvectis Pharma has reported Total Non-Current Liabilities for 5 years, with the latest figure at $13.3 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 49.49% year-over-year to $13.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.3 million (up 49.49% YoY) and the FY2025 annual result came in at $13.3 million, up 49.49% from the prior year.
• Total Non-Current Liabilities improved to $13.3 million in Q4 2025 per NVCT's latest filing, from $8.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $13.3 million in Q4 2025 and troughed at -$12.8 million in Q4 2021.
• A 5-year average of $4.5 million and a median of $7.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 148.23% in 2022, then advanced 12.9% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at -$12.8 million in 2021, then jumped by 148.23% to $6.2 million in 2022, then advanced by 12.9% to $7.0 million in 2023, then advanced by 27.35% to $8.9 million in 2024, then jumped by 49.49% to $13.3 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $13.3 million, $8.9 million, and $7.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.